Paclitaxel
Sep 30, 2011 at 11:22 | Source: Moneycontrol.com
Sep 30, 2011 at 11:01 | Source: Moneycontrol.com
Apr 10, 2008 at 10:52
Feb 26, 2008 at 14:36
Oct 16, 2007 at 08:18 | Source: Business Line
Photos »
/ 
News across the web »
Apr 24, 2012 at 06:11 | Source: Forbes
Mar 23, 2012 at 06:56 | Source: Forbes
Feb 20, 2012 at 03:36 | Source: Business Standard
Interact & exchange stock tips & market info »
Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab Ltd, ...
12.31 PM Oct 1st 2011
New Delhi: Drug firm Strides Arcolab on Friday said its subsidiary Onc...
12.28 PM Oct 1st 2011
Related News »
Six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon in more than 1000 patients were presented by Ralph Toelg, MD, Segeberger Heart Center Clinic, Germany ...
May 21, 2012 at 15:32 | Source: News-Medical.Net
Yarmouth, ME: The new FlowCAM® PV Series imaging particle analysis system from laboratory instrumentation manufacturer Fluid Imaging Technologies, Yarmouth, Maine (www.fluidimaging.com) automatically takes high-resolution, digital images of individual ...
May 15, 2012 at 12:33 | Source: ThomasNet Industrial News Room
Esperance initiates enrollment in EP-100 and paclitaxel Phase 2 combination trial for ovarian cancer
Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer. EP-100 is a targeted membrane ...
May 18, 2012 at 05:35 | Source: News-Medical.Net
In a 162-patient phase II trial for recurrent platinum-sensitive serous ovarian cancer, adding olaparib to carboplatin and paclitaxel for initial treatment followed by maintenance on olaparib led to median progression-free survival of 12.2 ...
May 25, 2012 at 17:22 | Source: MedPage Today
And it's been going on for a while. Back in 2008, Nexavar failed to show an effect in lung cancer in a trial dubbed ESCAPE (Evaluation of Sorafenib, Carboplatin, And Paclitaxel Efficacy in NSCLC). Sorafenib is the generic name for Nexavar ...
May 23, 2012 at 23:51 | Source: Daily Finance
The registry enrolled a population of mostly in-stent restenotic patients (87.7%), yet still had a very low major adverse cardiac event (MACE) rate of 8.7% and a revascularization rate of 3.2%. A further analysis of the diabetic subgroup of 363 patients ...
May 21, 2012 at 14:14 | Source: Phramalive.com
Six-month results from the BIOLUX P-I study, demonstrating excellent safety and efficacy results for the BIOTRONIK : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. Passeo-18 Lux : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .
May 21, 2012 at 11:58 | Source: PR Inside
[2] The much anticipated long-term follow-up of the Japanese GOG trial [3] looked at standard chemotherapy in ovarian cancer with carboplatin/[paclitaxel], with the paclitaxel being given every 3 weeks, vs the use of carboplatin in a standard ...
May 24, 2012 at 17:59 | Source: Medscape News
BATON ROUGE, La., May 17, 2012 /PRNewswire via COMTEX/ -- Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of ...
May 16, 2012 at 23:59 | Source: Marketwatch
A majority of the PCPs could not identify any of the late effects associated with cyclophosphamide, paclitaxel, and oxaliplatin. They were most familiar with doxorubicin toxicity, but only because 55% recognized cardiac dysfunction as a late ...
May 17, 2012 at 18:43 | Source: MedPage Today